Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 4Phase 3 3Phase 1/2 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4

Conditions

Leukemia, Myeloid, Acute 4Recurrence 2Leukemia 2

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × quizartinib × Clear all
NCT06824168 2025-12-04

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

Daiichi Sankyo

Phase 2 Recruiting
130 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02984995 2020-02-17

Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation

Daiichi Sankyo

Phase 2 Completed
37 enrolled 24 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01565668 2019-12-27

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Daiichi Sankyo

Phase 2 Completed
76 enrolled 17 charts
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00989261 2019-12-11

ACE

Daiichi Sankyo

Phase 2 Completed
333 enrolled 23 charts
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡